{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 49,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a split-layout with a dark sidebar for key facts and a white main area for clinical data and trial design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/26",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.61,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Non Inferiority Test comparing Etifoxine and Lorazepam over 35 days",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa706e3f-09a2-4fa5-833d-ff1e6736a18c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.36,
        "y": 0.65
      },
      "kind": "diagram",
      "text": "ONGOING PHASE 1 TRIAL: Part 1 Single Ascending Dose and Part 2 Multiple Ascending Dose",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e43d5a99-f49d-42ea-91ca-74051221e8cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.3,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "OWNERSHIP 53.8% PRODUCT Deuterated etifoxine HCl oral dosage form (GRX-917) PHARMACOLOGY Etifoxine facilitates endogenous production of neurosteroids... INDICATIONS Primary: Generalized Anxiety Disorder... CURRENT STATUS Phase 1 trial initiated in H1'21...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dfc05f5-aa52-481f-91bb-08fb93229b72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.36,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: HAM-A = Hamilton Anxiety Rating Scale... (1) (2) (3)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e81fc8f-c20d-4937-9731-5d221ea34579",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f22197cf-57aa-499f-8cbc-0994ebef2064",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "88b74d5a-f729-4056-bcb6-393defa045ca",
      "evidence": "title/headline: SUMMARY",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "ec743d88-ef3d-4fd1-918a-24e864448e77",
      "evidence": "Structured summary of product, pharmacology, and clinical status.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}